KR20120006063A - 셀룰라이트 치료용 아교질분해효소 - Google Patents

셀룰라이트 치료용 아교질분해효소 Download PDF

Info

Publication number
KR20120006063A
KR20120006063A KR1020117028099A KR20117028099A KR20120006063A KR 20120006063 A KR20120006063 A KR 20120006063A KR 1020117028099 A KR1020117028099 A KR 1020117028099A KR 20117028099 A KR20117028099 A KR 20117028099A KR 20120006063 A KR20120006063 A KR 20120006063A
Authority
KR
South Korea
Prior art keywords
gelatinase
cellulite
purified
injected
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117028099A
Other languages
English (en)
Korean (ko)
Inventor
마리 에이. 바데일멘테
알렉산더 비. 다굼
Original Assignee
더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 filed Critical 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕
Publication of KR20120006063A publication Critical patent/KR20120006063A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020117028099A 2006-02-22 2007-02-22 셀룰라이트 치료용 아교질분해효소 Ceased KR20120006063A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US60/775,690 2006-02-22
US11/703,269 2007-02-07
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087022877A Division KR20080108996A (ko) 2006-02-22 2007-02-22 셀룰라이트 치료용 아교질분해효소

Publications (1)

Publication Number Publication Date
KR20120006063A true KR20120006063A (ko) 2012-01-17

Family

ID=38325147

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117028099A Ceased KR20120006063A (ko) 2006-02-22 2007-02-22 셀룰라이트 치료용 아교질분해효소
KR1020087022877A Ceased KR20080108996A (ko) 2006-02-22 2007-02-22 셀룰라이트 치료용 아교질분해효소

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087022877A Ceased KR20080108996A (ko) 2006-02-22 2007-02-22 셀룰라이트 치료용 아교질분해효소

Country Status (19)

Country Link
US (4) US20070224184A1 (cg-RX-API-DMAC7.html)
EP (1) EP1991258B1 (cg-RX-API-DMAC7.html)
JP (5) JP5775658B2 (cg-RX-API-DMAC7.html)
KR (2) KR20120006063A (cg-RX-API-DMAC7.html)
AU (1) AU2007221225B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0708186A2 (cg-RX-API-DMAC7.html)
CA (1) CA2643171C (cg-RX-API-DMAC7.html)
DK (1) DK1991258T3 (cg-RX-API-DMAC7.html)
ES (1) ES2553184T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20151182T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025918T2 (cg-RX-API-DMAC7.html)
IL (1) IL193639A (cg-RX-API-DMAC7.html)
MX (1) MX2008010767A (cg-RX-API-DMAC7.html)
NZ (1) NZ570642A (cg-RX-API-DMAC7.html)
PL (1) PL1991258T3 (cg-RX-API-DMAC7.html)
PT (1) PT1991258E (cg-RX-API-DMAC7.html)
RS (1) RS54372B1 (cg-RX-API-DMAC7.html)
SI (1) SI1991258T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007100675A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US20060204488A1 (en) * 2005-01-21 2006-09-14 Badalamente Marie A Methods for treating adhesive capsulitis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
WO2008008468A2 (en) * 2006-07-14 2008-01-17 Duncan Diane I Compositions and methods for fat reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
JP5649589B2 (ja) * 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ1の温度感受性突然変異体およびその使用
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
JP2014530873A (ja) * 2011-10-21 2014-11-20 オーキシリウム インターナショナル ホールディングス,インコーポレイテッド Efpの治療または低減方法
EP4772625A2 (en) 2012-01-12 2026-07-08 Endo Biologics Limited Clostridium histolyticum enzyme
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
WO2014144859A1 (en) 2013-03-15 2014-09-18 Biospecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
DK3589204T3 (da) * 2017-03-01 2025-06-30 Endo Operations Ltd Apparat og fremgangsmåde til vurdering og behandling af cellulitis
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CA3112437A1 (en) * 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
MX2021008017A (es) * 2019-01-06 2021-08-05 Endo Global Aesthetics Ltd Formulaciones de colagenasa y metodos de produccion de las mismas.
AU2020366008B2 (en) 2019-10-15 2025-08-28 Biospecifics Technologies Corp. Treatment of uterine fibroids using purified collagenase
US20220409511A1 (en) * 2019-11-26 2022-12-29 Standard Of Care Corporation Hyaluronidase compositions and methods of using same to treat cellulite
AU2023269738A1 (en) 2022-05-10 2024-11-21 Endo Global Aesthetics Limited Methods of reducing collagenase-mediated bruising in a subject having cellulite

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
JP3028852B2 (ja) * 1994-06-24 2000-04-04 ロシュ ダイアグノスティックス コーポレーション ヒストリチクス菌から得られるコラゲナーゼおよび2つの他のプロテアーゼの精製混合物
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6335388B1 (en) * 1997-10-03 2002-01-01 Lavipharm Laboratories Inc. Prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
EP1207840B1 (en) * 1999-08-20 2004-10-13 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
US20060204488A1 (en) * 2005-01-21 2006-09-14 Badalamente Marie A Methods for treating adhesive capsulitis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US20210169844A1 (en) * 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions

Also Published As

Publication number Publication date
IL193639A0 (en) 2011-08-01
HUE025918T2 (en) 2016-05-30
WO2007100675A2 (en) 2007-09-07
BRPI0708186A2 (pt) 2011-05-24
MX2008010767A (es) 2008-09-01
EP1991258A2 (en) 2008-11-19
IL193639A (en) 2015-01-29
DK1991258T3 (en) 2015-11-16
SI1991258T1 (sl) 2016-02-29
JP6498167B2 (ja) 2019-04-10
RS54372B1 (sr) 2016-04-28
US10123959B2 (en) 2018-11-13
HRP20151182T1 (hr) 2016-01-01
JP2016204396A (ja) 2016-12-08
PT1991258E (pt) 2015-11-24
US20160279046A1 (en) 2016-09-29
KR20080108996A (ko) 2008-12-16
JP2020015771A (ja) 2020-01-30
US20070224184A1 (en) 2007-09-27
JP5775658B2 (ja) 2015-09-09
US20220249348A1 (en) 2022-08-11
JP2015134840A (ja) 2015-07-27
EP1991258B1 (en) 2015-08-12
ES2553184T3 (es) 2015-12-04
AU2007221225B2 (en) 2010-02-11
JP2009527570A (ja) 2009-07-30
PL1991258T3 (pl) 2016-04-29
NZ570642A (en) 2012-03-30
JP6853331B2 (ja) 2021-03-31
AU2007221225A1 (en) 2007-09-07
JP2018199733A (ja) 2018-12-20
CA2643171A1 (en) 2007-09-07
WO2007100675A3 (en) 2007-11-15
JP6649449B2 (ja) 2020-02-19
CA2643171C (en) 2018-10-02
US20190053995A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
JP6853331B2 (ja) セルライト処置用コラゲナーゼ
US4524065A (en) Method for the prevention and treatment of scars with enzymes
JP2020158521A (ja) Efpの治療または低減方法
US20090010918A1 (en) Methods for treatment using collagenase
HK1221143A1 (en) Method for treating adhesive joint capsule
US7964188B2 (en) Use of placental alkaline phosphatase to promote skin cell proliferation
WO2007100590A2 (en) Methods for treating cellulite
US20020081319A1 (en) Botulinum toxin therapy for hashimoto's thyroiditis
HK1115295B (en) Methods for treating adhesive capsulitis
HK1174532B (en) Compositions comprising botulinum toxin a or b for use in the treatment of osteoporosis

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20111124

Application number text: 1020087022877

Filing date: 20080919

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120221

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120517

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130329

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120517

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130628

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20130329

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20140326

Appeal identifier: 2013101004823

Request date: 20130628

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20130628

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20130628

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20121119

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2013101004823; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20130628

Effective date: 20140326

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20140326

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20130628

Decision date: 20140326

Appeal identifier: 2013101004823